Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: HIV Infections
Interventions: UC-781 carbomer gel, 0.1% and 0.25%; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 21 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Atlanta, Georgia • Arlington, Virginia

Conditions: Bacterial Vaginosis
Interventions: 5% Monolaurin Vaginal Gel, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Iowa City, Iowa • Durham, North Carolina • Cincinnati, Ohio

Conditions: Vaginitis
Interventions: Terazol or oral fluconazole for candidal vaginitis, Metronidazole or Clindamycin for Bacterial Vaginosis, Flagyl for definitively diagnosed vaginal trichomoniasis, Empiric Management; Drug · Other
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Atrophy of Vagina, Vaginal Ulceration, Vaginitis
Interventions: Estradiol, placebo; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Vulvo Vaginal Atrophy (VVA)
Interventions: Lasofoxifene Tartrate; Drug
Lead sponsor: Azure Biotech Inc.; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Pelvic Organ Prolapse, Uterovaginal Prolapse, Vaginal Vault Prolapse, Cystocele
Interventions: Absorbable Suture and Permanent Suture; Other
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Gestational Trophoblastic Disease
Interventions: Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List; Behavioral
Lead sponsor: Ira Winer; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Stress Urinary Incontinence
Interventions: tension-free vaginal tape, TVT-SECUR device; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years and older · Female only
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Durham, North Carolina + 4 more

Conditions: Vaginal Atrophy
Interventions: Placebo, DHEA; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 32
States / cities: Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more

Conditions: Cesarean Section, Endometritis, Surgical Wound Infection
Interventions: Vaginal cleansing before cesarean delivery; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions: Oral Encochleated Amphotericin B (CAMB); Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Fecal Incontinence
Interventions: Eclipse™ System; Device
Lead sponsor: Pelvalon, Inc.; Industry
Eligibility: 19 Years and older · Female only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • Boston, Massachusetts • Albuquerque, New Mexico + 8 more

Conditions: Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Vaginal Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Vulvar Cancer, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
Interventions: triapine, laboratory biomarker analysis, external beam radiation therapy, brachytherapy, cisplatin, pharmacological study; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Urinary Incontinence, Stress, Mixed Incontinence, Vaginal Vault Prolapse
Interventions: Vaginal Sling; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Norwalk, Connecticut

Conditions: Dyspareunia
Interventions: Prasterone; Drug
Lead sponsor: San Diego Sexual Medicine; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Vaginal Infection
Interventions: Metronidazole, Gel vehicle; Drug
Lead sponsor: Curatek Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 28 more

Conditions: Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
Interventions: Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions: Artesunate vaginal insert, Placebo vaginal insert; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 25 Years to 100 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Conditions: Cancer
Interventions: therapeutic autologous lymphocytes; Biological
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infection, Obstetric Labor Complications, Endometritis, Cesarean Delivery Affecting Fetus, Wounds Injuries
Interventions: Vaginal Preparation; Procedure
Lead sponsor: Womack Army Medical Center; Federal
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Bragg, North Carolina

Conditions: Female Patients With High Tone Pelvic Floor Dysfunction
Interventions: Vaginal Diazepam Suppository, Placebo Suppository; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions: stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies; Radiation · Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bacterial Vaginosis
Interventions: BNT331, Placebo; Drug · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Marrero, Louisiana • Metairie, Louisiana + 3 more

Conditions: Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma, Cutaneous Squamous Cell Cancer, Penile Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Vaginal Squamous Cell Carcinoma, Urethral Squamous Cell Carcinoma
Interventions: EVOLVE104; Drug
Lead sponsor: EvolveImmune United, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 10 more

Search by objective public record fields.

Botswana Study of UC-781 Vaginal Microbicide

Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network

Vaginal Creams to Reduce Vaginal Erosion in Pessary Users

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

Absorbable Suture vs Permanent Suture in Sacrospinous Ligament Suspension

ASk Questions in GYnecologic Oncology (ASQ-GYO)

Study Comparing TVT With TVT-SECUR for the Treatment of Stress Urinary Incontinence

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

A Clinical Evaluation of the Eclipse™ System, a Vaginal Bowel Control (VBC) Therapy for Fecal Incontinence in Women

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Treatment for Stress and Mixed Urinary Incontinence and Vaginal Vault Prolapse

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

Multi-Center Study of New Medications to Treat Vaginal Infections

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Gene Therapy in Treating Patients With Cancer

Vaginal Preparation and Azithromycin to Reduce Post Cesarean Infections

Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas